Overview
Pfizer Polska focuses on vaccines and the development of oncology therapies for frequently occurring and difficult-to-treat cancers. The company traces its origins to a chemical enterprise founded in New York in the mid-19th century by Charles Pfizer and Charles Erhardt.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2003-11-30. Active
51 1030 1335 0000 0005 0079 7500- 54 1030 1508 0000 0005 0079 7002
- 57 1030 1508 0000 0005 0079 7045
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 300.6KPLN 300,603 |
MSiG notices
10 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Aug 11, 2020 | Return of additional payments | |
| Aug 31, 2016 | Commercial Companies Code notice | |
| Jul 21, 2014 | Commercial Companies Code notice | |
| Oct 2, 2013 | Commercial Companies Code notice | |
| Feb 24, 2012 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
2 tenders recorded as contractor: 1 national ($84,860) and 1 EU ($4,136,249).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 10, 2025 | Dostawa produktów leczniczych z programów lekowych oraz różnych produktów leczniczych | $4.1M$4,136,249 | Copernicus Podmiot Leczniczy sp. z o.o. | |
| Oct 1, 2021 | Dostawa produktów leczniczych – lorlatinibum, dacomitinibum | $84,860$84,860 | Centrum Onkologii Im. Prof. Franciszka Łukaszczyka |
Public procurement disputes (KIO)
Pfizer Polska has been a party to 2 cases before the National Appeal Chamber (since 2018). It filed 2 appeals (2 dismissed).
Trademarks
Pfizer Polska currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2003.
| Mark | Protected until | |
|---|---|---|
| DLA ZDECYDOWANYCH NA RZUCENIE PALENIA(word) | – |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The President of the Management Board is authorized to submit declarations and sign on behalf of the company independently, whereas, in the case of a multi-member management board, the President of the Management Board independently, or two other members of the management board acting jointly, or a member of the management board acting jointly with a commercial proxy are authorized to do so.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Pfizer Luxembourg Sarl | 33,860 | $9,146,407.35 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Janssen-Cilag Polskasp. z o.o. | $323,933,929.12 | janssen.pl | ||
| MSD Polskasp. z o.o. | $99,368,700.21 | msd.pl |
Change history
| Date | Event | |
|---|---|---|
| 2018-09-13 | Address change (Postępu 17b, 02-676, Warszawa → Ul. Żwirki I Wigury 16b, 02-092, Warszawa) | |
| 2012-08-03 | Share capital change (73,860,000.00 PLN → 33,860,000.00 PLN) | |
| 2011-03-28 | Share capital change (17,860,000.00 PLN → 73,860,000.00 PLN) | |
| 2010-10-29 | Address change (Rzymowskiego 28, 02-697, Warszawa → Postępu 17b, 02-676, Warszawa) | |
| 2001-06-26 | Entered in the register |
FAQ
Last updated: 2026-10-07